Stifel’s Scott Devitt remains apprehensive on FB in his Q1 earnings preview, wary of sluggish revenue growth and business implications in a post-Cambridge Analytica era.
Monness Crespi’s Brian White still sees a “very attractive” stock in FB despite what initial drag comes from the Cambridge Analytica fiasco.
After being hit with the “darkest chapter” in history, GBH’s Daniel Ives anticipates extra attention will be paid to FB’s first quarter earnings show.
Ever since leaving the sidelines on FB last summer, Pivotal’s Brian Wieser is out with a slew of pessimistic reasons to run despite the bullish majority cheering on Wall Street.
Facebook CEO Mark Zuckerberg hit a home run on the stand in the courtroom before Congress; Aegis’ Victor Anthony shares his confident takeaways.
Though Monness Crespi’s Brian White understands the Cambridge Analytica fiasco will drag FB shares short-term, valuation is enticing.
It’s been a rough few weeks for social media giant Facebook (NASDAQ:FB). As we discussed just a few weeks ago, the company has been …
Facebook (NASDAQ:FB) co-founder Mark Zuckerberg endured five hours of questions in the US Senate on Tuesday, at one point conceding what’s probably inevitable: …
Wells Fargo’s Ken Sena is encouraged on FB, glad to see Zuckerberg’s focus on AI tools to detect future ‘attempted abuses’ like Cambridge Analytica from happening again.
GBH’s Daniel Ives wagers FB’s business model can weather the storm “intact” longer-term, but this may wind up being a “multi-year” process.
